On June 2, U.S. Rep. John Moolenaar introduced the bipartisan Biotech Investment National Security (BINSA) Act of 2026, aimed at safeguarding American pharmaceutical and biotechnology industries. The bill seeks to amend the Comprehensive Outbound Investment National Security (COINS) Act to include biotechnology in outbound investment screenings, responding to concerns over U.S. companies engaging with Chinese biotech firms. It mandates reviews by the U.S. Treasury on pharmaceutical licensing deals with Chinese entities and requires a defense assessment of the national security impact of U.S. investments in Chinese biotech. Both Moolenaar and cosponsor Rep. Debbie Dingell emphasized the need to maintain U.S. innovation leadership and protect national security.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://riponadvance.com/stories/no-offshoring-of-u-s-biotech-industry-says-moolenaar/
